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Background: The expected reduction in cervical cancer incidence as a result of increased access to antiretroviral
therapy is yet to be seen. In this study we investigated the effect of HIV infection and treatment on high-risk (hr)
human papilloma virus (HPV) prevalence and distribution.
Methods: Cervical cells from 515 (220 HIV positive and 295 HIV negative) women, recruited during community
cervical cancer screening programme in states of Ogun and Lagos and at the cervical cancer screen clinic, Nigerian
Institute of Medical Research Lagos were evaluated for the presence of 13 hr HPV genotypes by polymerase chain
reaction based assay.
Results: The prevalence of high-risk HPV was 19.6% in the studied population. HPV 16 (3.9%), 35 (3.5%), 58 (3.3%)
and 31 (3.3%) were the most common hr HPV infections detected. We observed that the prevalence of hr HPV was
higher in HIV positives (24.5%) than 15.9% in HIV negative women (OR = 1.7; 95% CI: 1.1-2.7). A multivariate logistic
regression analysis showed a lower hr HPV prevalence in HIV positive women on antiretroviral drugs (OR = 0.4;
95% CI: 0.3-0.5) and with CD4 count of 500 and above (OR = 0.7; 95% CI: 0.5-0.8). A higher prevalence of hr HPV was
also noted in HIV positive women with CD4 count < 200 cells/mm3 (OR = 2.4; 95% CI: 1.7-5.9).
Conclusion: HPV 16, 35, 58 and 31 genotypes were the most common hr HPV infection in our study group, which could
be regarded as high risk general population sample; with higher prevalence of HPV 16 and 35 in HIV positive women than
in HIV negative women. The use of antiretroviral drugs was found to be associated with a lower prevalence of hr HPV
infection, compared to those not on treatment. This study raises important issues that should be further investigated to
enable the development of robust cervical cancer prevention and control strategies for women in our setting.
Keywords: Human papilloma virus (HPV), Cervical cancer, HIV, Antiretroviral therapyBackground
In sub-Saharan Africa, the cervical cancer rates are on the
rise, paralleling the HIV epidemic [1,2]. The observed rise
in cervical cancer rate has been linked to the chronic devi-
ations in the immune systems due to HIV infection [3-5].
The impaired cell mediated immunity due to HIV infec-
tion results in the body’s inability to clear high risk (hr)
human papilloma virus (HPV) leading to the persistence* Correspondence: oezechi@yahoo.co.uk
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reproduction in any medium, provided the orof the virus in the cervix and eventual transformation of
the infected cervical cells to precancerous and cancerous
lesions [6]. With the diverse HIV epidemic in sub-Saharan
Africa, it is essential to consider how it may affect HPV
related cervical diseases including cervical cancer [7,8].
While studies from southern and eastern Africa have
noted a strong association between HIV, HPV co-infection
and the development of genital cancers [2,3,9,10], we were
unable to identify studies from the West African sub-
region that reported on HIV and HPV infection interac-
tions. Considering the HIV viral diversity across regions
and the differential effect of the viral strains on disease pro-
gression, it is expected that there may be regional variationsLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and development of cervical cancer [11,12].
The introduction of antiretroviral therapy in the last
few years and the increased access to HIV care in low-
income countries have resulted in the improvement of
clinical outcomes and life expectancy in HIV infected per-
sons [7,13,14]. Consequently, similar improvement was
projected in cervical cancer related morbidity and mortal-
ity [7,15,16]. However, decades after the introduction of
antiretroviral drugs, the expected reduction in new cer-
vical cancer cases and deaths is yet to be seen [16]. This
obvious absence of an association between the projected
improvement in cervical cancer outcomes and reported
cases globally has triggered investigations on the inter-
action between HIV, HPV and cervical cancer [17-19].
Epidemiological studies, including meta-analyses mostly
from high-income countries, have shown that HIV in-
fected women are at increased risk of infection with hr
HPV, yet studies from sub-Saharan Africa that accounts
for over 70% of global cervical cancer burden contribute
less than 1% of the evidence [2,9,19-21]. Prevention and
control strategies based on these data sets, might not be
effective in a sub-Saharan African context especially not
in West Africa where limited information on HPV and
HIV co-infection is available.
The two currently available vaccines that protect against
the acquisition of hr HPV are based on HPV 16 and 18, the
reported most common HPV genotypes globally [9,22-24].
However, there is increasing evidence of regional and sub-
regional variations in HPV genotype distribution, suggest-
ing that the current vaccines may not be as effective in the
sub-Saharan Africa region as projected [2,7,21,23-25]. Pre-
vious studies from sub-Saharan Africa show that although
the burden of HPV is high compared to Europe and North
America, a lower prevalence of HPV 16 and 18 and a
higher prevalence of other hr HPV genotypes such as HPV
31, 35 and 58, were observed [22-28]. A plausible assump-
tion could therefore be that other non-HPV 16 and 18
oncogenic genotypes may account for thousands of new
cases of cervical cancer that occur in this region annually.
In addition, since immunity to HPV virus like particle vac-
cines is type-specific, it is critical to characterize the distri-
bution of hr HPV genotypes in the West African sub
region with high burden of both HIV and HPV infection, in
order to develop an effective vaccine targeting women in
this region [2,7,22,23,28,29].
Unfortunately, several low-income countries, including
Nigeria, have approved and deployed the HPV vaccine
without such a detailed characterization of the HPV ge-
notypes in their settings [30]. Considering the amount of
resources invested in procuring and distributing this vac-
cine, it is imperative to conduct studies that will determine
the prevalence of prevailing HPV genotypes in these coun-
tries. Such information will potentially contribute to thedevelopment of second-generation HPV vaccines, which
will improve prevention and control of cervical cancer in
the sub-region [2,3].
Increasingly in Nigeria and other West African countries,
a large number of women have been offered an opportun-
ity to HIV treatment [13,31]. It is therefore important to
determine the impact of such long-term treatment on the
HPV prevalence and distribution as well as on cervical
cancer, in order to develop effective contextual cervical
cancer prevention for HIV positive women.
Since the introduction of HIV treatment in Nigeria in
2002, over 350,000 HIV infected adults have been initi-
ated on antiretroviral therapy [30] and 60% of these are
women [18]. Unfortunately, little or no information exists
on the prevalence, and distribution of HPV and cervical
cancer in this cohort [15,18,31]. In addition, extensive lit-
erature search shows no study that has evaluated the effect
of HIV infection, immunosuppression and antiretroviral
drug use on the burden and distribution of HPV infection.
This study therefore aims to determine the hr HPV
prevalence and distribution by HIV status among women
residing in two southwestern Nigerian states of Lagos
and Ogun. The effect of HIV infection, immunosuppres-
sion and antiretroviral drug use on the hr HPV distribu-
tion was also assessed.
Results
A total of 536 (231 HIV positive and 305 HIV negative)
women were enrolled into the study over a period of 12
months. The HPV results of 21 (3.9%) women were in-
valid and thus excluded from the analysis. There were no
differences in demographic profiles of these 21 women and
the remaining 515 (96.1%) with valid HPV results (p = 0.8).
Table 1 shows the sociodemographic characteristics of
the study participants by recruitment site. Although the
women recruited from NIMR site were slightly younger
and more likely to have a secondary education, the ob-
served differences were not statistically significant. Only
6.5% of the women recruited from the community were
living with HIV compared to 80.6% among the NIMR
site cohorts (p = 0.00).
Socio-demographic characteristics
The socio-demographic characteristics of 515 women
with valid HPV results by HIV status is shown in Table 2.
Of these women with valid results, 332 (64.5%) and 183
(35.5%) resided in rural and urban communities respect-
ively. The age of the women ranged from 18 – 81 years
with a median age of 37 years [IOR: 31–45]. The major-
ity (56.0%) were aged between 20 and 39 years. Over
sixty percent (60.4%) of the women belonged to the two
main ethic groups in southern Nigeria – Yoruba (33.3%)
and Igbo (27.1%), with the northern ethnic groups con-
stituting 19.7%. Approximately 67% were married and
Table 1 Comparison of the sociodemographic
characteristics of the women by recruitment sites
Characteristics
of participants
NIMR site Community site P value
n = 262 (%) n = 253 (%)
Median age (years) 35 [IQR: 31-41] 37 [IQR:32–47] 0.09
Educational level completed
< Secondary 53 (21.0) 69 (26.2) 0.20
≥ Secondary 199 (79.0) 194 (73.8)
Marital status
Unmarried 88 (34.9) 85 (32.3) 0.60
Married 164 (65.1) 178 (67.7)
Tribal group
Major Southern tribes 151 (59.9) 159 (60.4) 0.57
Northern tribes 54 (21.4) 48 (18.3)
Southern minority tribes 47 (18.7) 56 (21.3)
Residence
Urban 90 (35.7) 93 (35.4) 0.99
Rural 162 (64.3) 170 (64.6)
Occupation
Unemployed 34 (13.5) 38 (14.4) 0.85
Employed 218 (86.5) 225 (85.6)
Age at first intercourse (years)
< 15 27 (10.7) 30 (11.4) 0.91
≥ 15 225 (89.3) 223 (88.6)
Number of life time sexual partners
< 2 91 (36.1) 83 (31.6) 0.31
≥ 2 161 (63.9) 180 (68.4)
HIV status
Negative 49 (19.4) 246 (93.5) 0.00
Positive 203 (80.6) 17 (6.5)
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or widowed (11.7%). A majority of the women had at
least a secondary education (76.3%), were engaged in an
income generating activity (86.0%) and had at least one
previous delivery (77.1%). The age of the women at their
first intercourse ranged from 9–38 years with a mean of
20.4 ± 3.9 years. Over two-thirds of the women in the
study reported total lifetime sexual partner between 2
and 10 with a mean of 2.9 ± 2.5.
Laboratory and treatment characteristics of the HIV
positive women
The HIV related characteristics of HIV positive women en-
rolled in the study is presented in Table 3. The CD4 cell
count of the women ranged from 10 to 1651 cells/mm 3
with a median of 500 [IQR: 347–685]. The majority (50.9%)
of the women had CD4 cells counts above 500 cells/mm 3.
The plasma viral load levels ranged from undetectablelevels (<20) to 657,899 copies/ml with a median of 200
[IQR: 200–2270]. Over 60% had viral loads less than 1000
copies/ml. While the majority (72.3%) were already on
antiretroviral therapy (ART) at enrolment for a period
ranging from 3 months to 8 years, others were yet to
start ART (27.7%).
High-risk HPV genotype distribution
Table 4 shows the distribution of hr HPV strains by HIV
status, the Odds Ratios and 95% CI, after adjustment for
age, antiretroviral treatment and life time sexual partner-
ship. The hr HPV prevalence in the study was 19.6% and
multiple hr HPV infections were detected in 5.4% of the
women. The most commonly detected hr HPV geno-
types were 16 (3.9%), 35 (3.5%), 58 (3.3%) and 31 (3.3%),
followed by 18 (2.3%), 52 (2.3%) and 51 (1.9%). HPV geno-
types 16 and 18 infections were detected in 32 (21.7%) of
the 101 hr HPV infected women in this study.
The prevalence of hr HPV was higher in HIV positive
(24.5%) women than in HIV negative women (15.9%;
OR = 1.7; 95% CI: 1.1-2.7). Multiple infection rates were
also higher in the HIV positive women (8.2%) compared
to 3.9% in HIV negative women (OR = 2.6; 95% CI: 1.3-
5.3). A similar trend was observed in HPV 16 (OR = 3.1;
95% CI: 1.3-6.3) and HPV 35 (OR = 3.6; 95% CI: 1.4-6.9)
infections. No difference was observed in other 11 hr
HPV genotypes studied.
Among the HIV positive women, HPV 16 and 18 con-
stituted 32.7% [18] of hr HPV infections compared to
30.6% [14] among HIV negative women, which was not
statistically significant (p = 0.99).
Association between HIV infection, treatment and hr
HPV infection
To determine the association between HIV infection, treat-
ment and hr HPV infection, we compared the sociodemo-
graphic and HIV related characteristics with hr HPV status
among the women in the study (Tables 2, 3 and 5). Differ-
ences in the status of hr HPV infection were found for
various variables first at univariate analysis and then multi-
variate analysis for variables found significant at univariate
analysis. At multivariate model to avoid over or under cor-
rection for confounding variables, the data were analyzed
and reported in three models (Table 5).
At univariate analysis (Tables 2 and 3), a greater percent-
age of women with hr HPV infection status were less than
25 years (OR: 2.2; 95% CI: 1.1 – 4.6), have never married
(OR: 1.9; 95% CI: 1.1-3.4), resides in an urban community
(OR: 1.6; 95% CI: 1.0-2.6), and have had at least two life
time sexual partners (OR: 1.9; 95% CI: 1.1-1.3.3). HIV posi-
tive women (OR: 1.7; 95% CI: 1.1 – 2.7), those with CD4
cell count less than 200 (OR: 3.1; 95% CI: 1.1-9.1) and viral
load greater than 10,000 copies (OR: 3.3; 95% CI: 1.0-10.9)
were also found to be at increased risk of hr HPV infection.
Table 2 Socio-demographic characteristics of the 515 women by hr HPV infection status
Characteristics Number of women (%) hr HPV infection status OR; 95% Confidence
interval (CI)n = 515 hr HPV positive status hr HPV negative status
n = 101 (%) n = 414 (%)
Age (years)
< 25 51 (9.9) 19 (37.3) 32 (62.7) 2.2 (1.1-4.6)
25 – 34 165 (32.0) 35 (26.9) 130 (73.1) 1 (ref)
≥ 35 299 (58.1) 47 (18.7) 252 (81.3) 0.7 (0.4-1.2)
Educational level completed
< Secondary 122 (13.7) 23 (18.9) 99 (81.1) 0.9 (0.5-1.6)
≥ Secondary 393 (76.3) 78 (19.8) 315 (80.2) 1 (ref)
Marital status
Never married 86 (16.7) 24 (27.9) 62 (72.1) 1.9 (1.1-3.4)
Married 342 (66.4) 58 (16.9) 284 (83.1) 1 (ref)
Divorced/Separated/Widow 87 (16.9) 19 (21.8) 68 (78.2) 1.4 (0.7-2.5)
Tribal group
Major Southern tribes 310 (60.2) 57 (18.4) 253 (81.6) 1 (ref)
Northern tribes 102 (19.8) 21 (20.6) 81 (79.4) 1.2 (0.6-2.1)
Southern minority tribes 103 (20.0) 23 (22.3) 80 (77.7) 1.3 (0.7-2.3)
Residence
Urban 183 (35.5) 44 (24.0) 139 (76.0) 1.6 (1.0-2.6)
Rural 332 (64.5) 54 (16.3) 278 (83.7) 1 (ref)
Occupation
Unemployed 72 (14.0) 20 (27.8) 52 (72.2) 1.7 (0.9-3.1)
Employed 443 (86.0) 81 (18.2) 362 (81.8) 1 (ref)
Age at first intercourse (years)
< 15 57 (11.1) 13 (22.8) 44 (77.2) 1.3 (0.6-2.6)
15 – 24 378 (73.3) 72 (19.0) 306 (81.0) 1 (ref)
≥ 25 80 (15.5) 16 (20.0) 64 (80.0) 1.1 (0.6-2.0)
Number of life time sexual partners
1 174 (33.8) 23 (13.2) 151 (86.8) 1 (ref)
2 – 4 256 (49.7) 57 (22.3) 199 (77.7) 1.9 (1.1-3.3)
≥ 5 85 (16.5) 21 (24.7) 64 (75.3) 2.2 (1.1-4.4)
Number of deliveries
0 118 (22.9) 21 (17.8) 97 (82.2) 0.9 (0.5-1.6)
1 – 4 244 (47.4) 48 (19.7) 196 (80.3) 1 (ref)
≥ 5 153 (29.7) 32 (20.9) 121 (79.1) 1.1 (0.6-1.8)
HIV status
Negative 295 (57.3) 47 (15.9) 248 (84.1) 1 (ref)
Positive 220 (42.7) 54 (24.5) 166 (75.5) 1.7 (1.1-2.7)
Ezechi et al. Virology Journal 2014, 11:5 Page 4 of 11
http://www.virologyj.com/content/11/1/5However HIV positive women on antiretroviral drugs
were found to be at a reduced risk of hr HPV infection
(OR: 0.4; 95% CI: 0.2-0.7) compared to HIV positive women
not yet on treatment.
Table 5 shows the result of the multivariate analysis in
three models to evaluate the relationship between HIVrelated variables and hr HPV status. Though HIV infection,
CD4 count, high HIV viral load and the use of antiretroviral
drugs were found to be associated with hr HPV infection
status at the initial model, after adjusting for age only three
variables of HIV positive status, CD4 count and use of anti-
retroviral drugs retained their independent association with
Table 3 Laboratory and treatment characteristics of the 220 HIV positive women by hr HPV infection status
Variables Number of women
n = 220 (%)
hr HPV infection status OR; 95% confidence
interval (CI)hr HPV positive status hr HPV negative status
n = 101 (%) n = 414 (%)
CD4 cell count (Cells/mm3)
< 200 22 (10.0) 12 (54.5) 10 (45.5) 3.1 (1.1-9.1)
200 – 499 86 (39.1) 24 (27.9) 62 (72.1) 1 (ref)
>500 112 (50.9) 18 (16.1) 94 (83.9) 0.5 (0.2-1.0)
HIV viral load (Copies/ml)
<1000 136 (61.8) 19 (14.0) 117 (86.0) 0.5 (0.2-1.8)
1000 – 9999 26 (121.8) 6 (23.1) 20 (76.9) 1 (ref)
>10,000 58 (26.4) 29 (50.0) 29 (50.0) 3.3 (1.1-10.9)
Antiretroviral drug use
Not on drugs 61 (27.7) 24 (39.3) 37 (60.7) 1 (ref)
On drugs 159 (72.3) 30 (18.9) 129 (81.1) 0.4 (0.2-0.7)
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treatment) and final models (in addition to the adjustment
made in the initial and 2nd model, further adjustments
were made for life time sexual partnership, type of commu-
nity and marital status. In the final model, women infected
with HIV infection (OR: 1.8; 95% CI: 1.4-2.2) and had CD4
cell count < 200 cells (OR: 2.4; 95% CI: 1.7- 5.9) were found
to be at increased risk of hr HPV infection. While HIV
positive women on antiretroviral therapy (OR: 0.4; 95% CI:
0.3-0.5) and with CD4 count of 500 cells and above (OR:Table 4 The distribution of hr HPV, overall and by specific ge
hr HPV status All women
n = 515 (%)
HIV positive
n = 220 (%)
HR HPV negative 414 (80.4) 166 (75.4)
HR HPV positive 101 (19.6) 54 (24.6)
HPV 16 20 (3.9) 14 (5.4)
HPV 18 12 (2.3) 3 (1.4)
HPV 31 17 (3.3) 12 (5.5)
HPV 33 2 (0.4) 1 (0.5)
HPV 35 18 (3.5) 13 (5.9)
HPV 39 3 (0.6) 1 (0.5)
HPV 45 7 (1.4) 3 (1.4)
HPV 51 10 (1.9) 5 (2.3)
HPV 52 12 (2.3) 6 (2.7)
HPV 56 6 (1.2) 2 (0.9)
HPV 58 18 (3.5) 9 (4.1)
HPV 59 3 (0.6) 1 (0.5)
HPV 68 4 (0.8) 1 (0.5)
Multiple HPV infection 28 (5.4) 18 (8.2)
aadjusted for confounders of age, antiretroviral drug use and number of life time se0.7; 95% CI: 0.5-0.8) were found to be at lower likelihood of
having hr HPV infection compared with those not on treat-
ment or with CD4 count less than 500 cells.
Discussion
Among women enrolled in this study, the overall preva-
lence of hr HPV infection was 19.6% and the prevalence
of multiple hr HPV infection was 5.4%. The prevalence
of hr HPV infection in HIV positive women (24.5%) was
significantly higher than the prevalence in HIV negativenotypes among the women by HIV status
HIV negative
n = 295 (%)
OR (95% CI)
Crude Adjusteda
248 (84.1) 1 (ref) 1 (ref)
47 (15.9) 1.9 (1.2–2.9) 1.7 (1.1-3.1)
6 (2.6) 3.3 (1.1-9.7) 3.1 (1.3-6.3)
9 (3.10 0.4 (0.1-1.8) 0.4 (0.2-1.9)
5 (1.7) 3.1 (1.1-11.1) 1.9 (0.9-8.1)
1 (0.3) 1.3 (0.0-49.3 1.1 (0.0-46.1)
5 (1.7) 3.4 (1.2-11.9) 3.6 (1.4-6.9)
2 (0.7) 0.7 (0.1-9.4) 0.6 (0.2-9.1)
4 (1.4) 1.0 (0.2-5.4) 0.9 (0.1-5.9)
5 (1.7) 1.4 (0.3-5.4 1.4 (0.4-5.5)
6 (2.0) 1.4 (0.4-4.8) 1.3 (0.2-5.1)
4 (1.4) 0.7 (0.1-4.3) 0.7 (0.2-6.9)
9 (3.5) 1.4 (0.5-3.9) 1.2 (0.3-4.1)
2 (0.7) 0.7 (0.02-9.4) 0.5 (0.1-10.1)
3 (1.0) 0.4 (0.02-4.8) 0.4 (0.1-6.1)
10 (3.9) 2.5 (1.1-6.1) 2.6 (1.3-5.3)
xual partners.
Table 5 Variables independently associated with hr HPV




Initial modela 2nd Modelb Final modelc
OR (95% CI) OR (95% CI) OR (95% CI)
HIV status (515)
Negative 1 (ref) 1 (ref) 1 (ref)
Positive 1.7 (1.3 -2.5) 1.7 (1.3-2.5) 1.8 (1.4-2.2)
Antiretroviral drug use (220)
Not on drugs 1 (ref) 1 (ref) 1 (ref)
On drugs 0.4 (0.3 - 0.9) 0.4 (0.3 - 0.9) 0.4 (0.3-0.5)
CD4 cell count (220)
<200 2.9 (1.3-7.1) 2.5 (1.5-6.1) 2.4 (1.7-5.9)
200 – 499 1 (ref) 1 (ref) 1 (ref)
500 and above 0.6 (0.3-1.0) 0.6 (0.5-0.9) 0.7 (0.5-0.8)
Viral load (220)
<1000 0.5 (0.2-1.9) 0.6 (0.4 -1.3) 0.6 (0.3 -1.4)
1000 – 10,000 1 (ref) 1 (ref) 1 (ref)
≥ 10,000 3.1 (1.1-9.9) 3.1 ( 0.9- 8.7) 2.7 (0.6- 8.1)
aadjusted for age badjust for HIV status and antiretroviral drug use cin addition
to a and c adjusted for type of community, life time sexual partner and
marital status.
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mon hr HPV strains were 16 (3.9%), 35 (3.5%), 58 (3.3%)
and 31(3.3%), however it was only HPV 16 (OR: 3.1; 95%
CI: 1.3-6.3) and 35 (OR: 3.6; 95% CI: 1.4-6.9) genotypes that
were found to have significant association with HIV infec-
tion. HIV positive women with a CD4 count of < 200 were
found to be at higher risk of hr HPV infection than their
counterpart with higher CD4 cell count (OR: 2.4; 95% CI:
1.7- 5.9). The use of antiretroviral drugs (OR: 0.4; 95%
CI: 0.3-0.5) and CD4 cell count above 500 cells (OR: 0.7;
95% CI: 0.5-0.8) were found to be associated with a lower
HPV prevalence than HIV positive women not on therapy
or with CD4 count <500 cells respectively.
The overall hr HPV prevalence of 19.6% though similar
to 18.3% reported from Ibadan, Nigeria [23], is higher than
14.6% reported from Irun, a rural and agrarian community
in Osun state of Nigeria [24], suggesting a possible lower
prevalence of hr HPV infection in rural communities. The
present study further supports the reported rural–urban
differences in HPV prevalence as the prevalence of hr
HPV in rural communities (16.1%) was significantly lower
than 23.9% in the urban settings. This finding is also con-
firmed by previous research in low-income countries, in-
cluding Nigeria, that the prevalence of sexually transmitted
infection is higher in urban than in rural areas [32,33]. This
may be related to varying sexual behavior, lifetime sexual
partnership and practices in the two settings or selection
bias in various studies.HPV 16, 35, 58 and 31 were the most common hr
HPV genotype detected in this study, which is similar to
findings reported by previous studies in our sub region
[23,24,34]. However, the findings differed from the hr
HPV distribution patterns described in other sub-
Saharan African regions, Americas, Asia and Europe
[2,3,9,21,23-25,27,28,33,35]. While HPV 16 and 18 were
the commonest genotype detected in Europe and North
America [3,9,32], in East Africa HPV 52 and 16 were the
most common [2,3,9,25,27]. In southern Africa, though
the predominance of HPV 16 and 18 were retained,
HPV 16 lost its position as the most common next to
HPV 18 [2,27]. This confirms the assertion by Ngandwe
et al. that in sub-Saharan Africa, other hr genotypes
other than HPV 16 and 18 may play a more major role
in evolution of cervical cancer than previously thought
[35]. However this needs to be further confirmed in
samples of women with invasive cervical cancer.
In the studied sample, the prevalence of hr HPV and
multiple hr HPV infection were found to be significantly
higher in HIV positive women (24.6% and 8.2%) than in
HIV negative women (15.9% and 3.9%) respectively (OR:
1.7; 95% CI: 1.1-3.1, OR: 2.6; 1.3-5.3). However statistically
significant association with HIV infection was noted only
for hr genotypes HPV 35 and 16 after controlling for con-
founders (see Table 4). Women infected with HIV were
3.6 and 3.1 times likely to be infected with HPV 35 (OR:
3.6; 95% CI: 1.4-6.9) and 16 (OR: 3.1; 95% CI: 1.3-6.3) re-
spectively than HIV negative women. The reported higher
hr HPV prevalence in HIV infected women noted in this
study were similar to previous observations from other re-
gions of Africa, south America and Europe connoting that
HIV infected women are at increased risk of hr HPV in-
fection [2,3,13,26,27,34-37]. The observed increase in
prevalence has been attributed to HIV related immuno-
suppression [6,32,38]. Strickler and colleagues confirmed
in two separate studies an increased prevalence of HPV,
persistence and decreased resolution of HPV infection in
HIV positive women compared to HIV negative women
[18,39]. Clifford and colleagues showed in their meta-
analysis involving 20 publications that apart from viral
types, immune-suppression of HIV infection significantly
increased the risk for HPV infection and invasive cancer
[38]. In addition, the reported more frequent multiple
HPV types in HIV-positive women was consistent with
previous reports [8-10], and may be attributable to the
common mode of transmission of HPV and HIV; persist-
ence of HPV as a result of the inability to clear HPV infec-
tions; as well as reactivation of latent HPV infections [38].
The higher prevalence of hr HPV infection in HIV posi-
tive women with CD4 count <200 cells/mm3 and signifi-
cantly lower prevalence in those with CD4 count >500 cells
found in this study further confirms the results of several
studies that have consistently shown a higher prevalence
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tions in HIV positive women with CD4 < 200 cells/mm 3
[4,6,18,38,39]. The noted associations are reportedly due
to severe immune-deficiency. In the presence of severe
immunodeficiency the body’s capacity to suppress latent
infection is impaired and the risk of HPV infection is in-
creased [17,18,39,40]. HIV infection could also impact on
the natural history of HPV by impairing the virus’s ability
to escape the immune system [4,17,18,40].
In this study we were unable to confirm the earlier re-
ported role of high HIV viral load on the prevalence and
burden of hr HPV infection [4,10], as the initial associ-
ation of hr HPV infection and viral load >10,000 copies
(OR: 3.1; 95% CI: 1.1-9.9) was not retained after control-
ling for confounders in the 2nd and final models (see
Table 5). The reported association in the other studies
may be due to confounders of HIV treatment, CD4 cell
count and sexual behaviour which were controlled for in
this study [4,10,18,38].
A statistically significant association was found between
hr HPV and use of antiretroviral drugs (ART) as HIV
positive women on antiretroviral therapy were found to be
at lower risk of acquiring hr HPV infection than those not
on antiretroviral drugs (OR: 0.4; 95% CI: 0.3-0.5). This
finding supports previous studies and also the hypothesis
that ART has the potential to restore the immune re-
sponse against HPV [40-44]. The use of ART may there-
fore reduce HPV persistence and reduce the occurrence
of HPV infection and even favour regression [8,21,40].
The combined relatively low prevalence of HPV vac-
cine related HPV 16 and 18 reported in this study were
comparable both in HIV positive and negative women.
Also the combined prevalence in this study corroborate
other findings reported from our sub-region [23,24,34],
suggesting that the currently available vaccine based on
HPV 16 and 18 will be useful in only a minority of women
irrespective of their HIV status, as genotypes other than
HPV 16 and 18 were found to constitute the majority of
the circulating hr HPV genotypes.
Our results need to be interpreted with caution, as it
was conducted in 2 states out of 36 states in Nigeria.
However, Lagos as the commercial capital of Nigeria and
former administrative capital is the sociocultural, behav-
ioural and diverse ethnic melting point of the country. As
such information obtained may be generalizable to the en-
tire country. Secondly, being a cross-sectional study, it
may have missed possible variations of specific HPV types
overtime. However, as the study was conducted over a one
year period this concern may have been taken care of. In
addition, the recruitment of about 90% HIV positive group
from the clinic and majority of HIV negative women from
the community may have introduced some selection bias.
This method of recruitment was used because of low HIV
prevalence in Lagos and Ogun states. The HIV positivewomen in the HIV treatment Centre were used in this
study because over 65% of them reside in the same setting
as the women recruited in the community. Secondly if this
strategy was not adopted, sufficient number of HIV posi-
tive women and those on antiretroviral therapy will not be
recruited. In addition, there were no statistically signifi-
cant differences in the sociodemographic characteristics
between the two groups except in their HIV status. Mindful
of the possible effect of this on the validity of our results,
we controlled for the possible confounders in multivariate
logistic regression using three models.
The major strength of this study is the recruitment of
women of diverse characteristics including HIV positive
and negative women from rural as well as urban areas,
those on treatment and not on treatment, thus increasing
the feasibility of generalizing the findings. It is also the
first study, to the best of our knowledge, in our sub-region
that evaluated the effect of HIV infection and treatment
on hr HPV prevalence and distribution. In addition two
sample size estimates were calculated (prevalence and
comparison of proportion in two groups). This assured us
that the study had sufficient statistical power to detect the
expected effects.Conclusion
HPV 16, 35, 58 and 31 were the most common hr HPV
infections in the population studied and HIV positive
women are at higher risk of acquiring HPV infection.
The current HPV vaccine prevents genotypes 16 and 18,
which accounted for only a minority of hr HPV infection
(21.7%) with no significant difference between HIV negative
and positive women. The use of antiretroviral drugs was
found to be protective against HPV infection. Although fur-
ther studies with a larger number of participants and wider
geographic spread are required in order to comprehensively
characterize the HPV distribution in Nigerian women, this
study raises important issues such as;
1) The effectiveness of the currently available HPV
vaccine in our sub region.
2) The rate of HPV 35, 58 and 31 in invasive cancer
cells in our setting.
3) The role of long term antiretroviral drugs on
cervical cancer incidence, that should be further
investigated to enable the development of a robust
cervical cancer prevention and control strategy for
all women in our sub region.Methods
Study design
A cross sectional study among women of known HIV
status enrolled into a study primarily to evaluate the
utility of direct visual inspection of the cervix in
Ezechi et al. Virology Journal 2014, 11:5 Page 8 of 11
http://www.virologyj.com/content/11/1/5diagnosing premalignant lesions of the cervix in HIV
positive women.
Study setting
The study was conducted at Nigerian Institute of Medical
Research (NIMR) Lagos, cervical cancer screening Clinic
and during community cervical cancer screening outreach
programs in Lagos and Ogun States of Nigeria. These are
two contiguous states in southwestern Nigeria, which to-
gether are inhabited by approximately 13 million people of
whom 48.8% are women [45]. The cervical cancer screen-
ing outreach programs were conducted in 10 communi-
ties. Three urban (Surulere, Ikeja and Gbagada) and four
rural (Mushin, Iju, Ikorodu and Egbeda) communities be-
long to Lagos State while one urban (Sagamu) and two
rural (Ifo and Ibafo) are situated in Ogun state. The aver-
age distance from the communities to NIMR ranged from
2 to 70 kilometers. The population in the rural communi-
ties to a large extent is of low socioeconomic status and
poorly educated in comparison to the urban population
with relatively higher socioeconomic status and education.
Within the urban communities however, pockets of slums
exist, with living conditions similar to or worse than those
in the rural areas.
NIMR is the apex medical research institution in Nigeria
charged with the responsibility to conduct research into
diseases of public health importance. The Institute cur-
rently provides comprehensive HIV care, treatment and
support for over 20,000 patients of whom 62.9% are
women. Over seventy-five percent of the patients come
from Lagos and Ogun state (where majority of the HIV
negative women in this study were recruited during com-
munity outreach programmes); with the remaining from
the other neigbouring states and west African countries.
All services at the Centre are provided free of charge.
Study population
The study population was adult females aged 18 years and
above seen at the cervical cancer screening clinic, Nigerian
Institute of Medical Research Lagos and during commu-
nity cervical cancer screening outreach programmes. While
80% of the HIV positive women were recruited from the
cervical cancer screening clinic; the remaining were re-
cruited during the community outreach. The HIV nega-
tives were mainly recruited from the women who attended
the various community outreaches cervical screening pro-
gramme. However it is important to note that over 50% of
the patient in our HIV treatment centre are from these
same communities. The women were recruited after ob-
taining a written informed consent in both settings.
Sample size determination
The sample size for this study was based on a reference
prevalence value of hr HPV among women in acommunity based study conducted in Ibadan, Nigeria of
18.3% [21]. The study sample size was calculated accord-
ing to the following formula: N = Zα2P (1-P)/d2, where
Zα is the Z statistic for a 95% confidence level, N is the
sample size, p is the prevalence of hr HPV, and d is the
precision [46]. Based on this calculation, screening 229
women aged 18 years and above was considered sufficient
for identifying women with hr HPV in each arm. To fur-
ther ensure that the study is sufficiently powered to detect
the effect of HIV treatment on hr HPV, a power calcula-
tion was further performed. Calculator from the EpiTools






These site calculators use standard assumptions based
on normal approximation to the binomial distribution.
The basic formula for comparing two proportions is: N =
(Zα + Zβ) × ((p1)(1-p1) + (p2)(1-p2))/(p1-p2)
2, where we used
confidence interval of 95% for computation (Zα = 1.96). As-
suming sample sizes of 57 for each group and using an es-
timate of 40% in ARV drug naive group and 15% in ARV
treatment group (difference of 25%), we arrived at 80%
power to detect reduction in the rate of hr HPV in the
antiretroviral drug group using a 2-tailed test.
Data collection
Information on the socio-demographic, sexual and repro-
ductive characteristics, HIV status and treatment history
of women who consented to be part of the study were col-
lected by trained female research assistants using a study
record form designed for this study by OE, the Principal
Investigator (PI). The laboratory information (HIV status,
CD4 cell count, HIV plasma viral load and hr HPV geno-
types) was extracted from the participant’s laboratory re-
sults and entered into the relevant portion of the study
record form. The entered information was cross checked
with the laboratory results by the PI to avoid entry error.
Cervical sample collection
Trained Midwives and Doctors conducted the pelvic
examination. Samples of cervical exfoliated cells from the
ectocervix and endocervix were obtained using a cyto-
brush. The tip of the cytobrush, which contains cellular
material was then placed into a transport medium and
stored at 2-8°C immediately. All specimens were coded
with the participants study number.
Laboratory tests
HIV test
HIV test was conducted according to Nigerian National
HIV testing and counseling guidelines in women with
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Diagnosis was based on positive test on double ELISA
based algorithm. However before initiation of antiretroviral
therapy the initial test was reconfirmed using Western Blot.
Viral load and CD4 cell count test
The tests were conducted at the Human Virology Labora-
tory, NIMR. Whole blood of the HIV positive women
were used to perform CD4 assay using the Cyflow Coun-
ter and Kits (Partec, Germany) according to the Manufac-
turer’s instructions. The viral load assay was performed
using Roche Amplicor HIV-1 monitor test (version 1.5)
according to manufacturer’s instruction.
DNA extraction and detection
All samples were subjected to centrifugation at 200 rpm
for 10 minutes. Precipitated cells were digested using diges-
tion buffer containing protein kinase. HPV DNA was
extracted with phenol- chloroform, re-suspended in 100 μl
elution buffer and stored at −20°C prior to molecular ana-
lysis. Quality and integrity of DNA sample for PCR was
verified by amplification of a 268 base pair region of human
B-globin gene. Specimens with negative internal control
amplification were excluded. All the B-globin positive sam-
ples were amplified with HPV4A ACE PC (Inqaba, South
Africa). To detect the genotype of the 13 high risk HPV
strains, samples were amplified using the specific primers
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68.
Data analysis
Information entered into the study record forms were
coded and analyzed using the SPSS version 19.0 (SPSS
Inc. Chicago, IL) statistical packages. The main outcome
variable was hr HPV positivity, defined as presence of
any of the 13 virus strains mentioned above. First level
analysis was to determine the overall prevalence of hr
HPV (defined as presence of any of the 13 hr HPV strains)
among the women and the prevalence of specific hr HPV
strains by HIV status and adjusted for age, treatment his-
tory and life time sexual partnership. Since the hr HPV
prevalence was not very high, we used multivariate model
to estimate the odds ratio for independent variables asso-
ciated with hr HPV infection. Bivariate analysis was first
performed to assess the association of variables with hr
HPV infection. All factors independently associated with
hr HPV infection in the bivariate analysis were considered
as confounders and introduced in a step wise manner in
the models. In the first step, we started with the crude as-
sociation between the variables and main outcome ad-
justed by age (Initial Model), then we adjusted for HIV
status and treatment (Model 2), and finally in a step wise
manner introduced the variables that were shown to be
statistically associated with hr HPV infection in the bivari-
ate analysis (Final Model). The results were reported inpercentages, Odds ratios (OR) or adjusted ORs and their
95% confidence intervals (CI).
Ethical considerations
Approval for the study was obtained from the Institu-
tional Review Board, Nigerian Institute of Medical Re-
search, Lagos Nigeria. A written informed consent was
obtained from the women invited to be part of the study
after detailed information about the study. Impartial wit-
nesses who were not members of NIMR staff assisted
the consenting process for the low literates.
Definition of variables
 HIV treatment status: The use of antiretroviral
therapy among the HIV positive women for more
than 3 months.
 Viral load: The level of HIV RNA copies/mL of
plasma measured by Roche Ampliclor HIV-1
monitor test (version 1.5).
 CD4 Cell count: The level of body’s immunity
measured as the number of CD4 T lymphocytes per
mm3 of blood by Cyflow Counter and Kits.
 High risk Human Papilloma Virus (hr HPV): The 13
oncogenic HPV strains of 16, 18, 31, 33, 35, 39, 45,
51, 56, 58, 59 and 68.
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